Adam Elkhaled1,
Llewellyn Jalbert1, Hikari Yoshihara1, Gabriella Bourne1,
Joanna Phillips2, Soonmee Cha1, Susan M. Chang3,
Radhika Srinivasan1, Sarah J. Nelson1,4
1Department of
Radiology & Biomedical Imaging, University of California, San Francisco,
San Francisco, CA, USA; 2Department of Pathology, University of
California, San Francisco; 3Department of Neurological Surgery,
University of California, San Francisco; 4Department of
Bioengineering & Therapeutic Sciences, University of California, San
Francisco
Low grade gliomas with mutations in the isocitrate dehydrogenase-1 (IDH1) gene carry a significant survival advantage, and have recently been shown to manifest excessive production of 2-hydroxyglutarate (2HG). Given the potential prognostic value of 2HG as an onco-metabolite, we sought to characterize differences in metabolite levels between gliomas of distinct origin and grade using